Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurofibromatosis Type 1: early-phase trial registry
5 of 18 indexed Neurofibromatosis Type 1 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 5 currently recruiting · #953 of 28,707 conditions by registered trial count
Neurofibromatosis Type 1: 18 US clinical trials tracked, 5 recruiting.
Neurofibromatosis Type 1 is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition neurofibromatosis-type-1
OPEN 5 | RECR 28% | LATE 2 | EARLY 8 | RANK #953 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Diabetic Peripheral Neuropathy (28% recruiting · 18 trials)
Neurofibromatosis Type 1 lists 5 open slots (28% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurofibromatosis Type 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurofibromatosis Type 1 is recruiting below its size-band peers.
5 of 18 indexed trials (27.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neurofibromatosis Type 1 research.
National Cancer Institute (NCI) accounts for 7 of 18 trials (38.9%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Neurofibromatosis Type 1 trials plan to enrol fewer than 100 people.
Median target enrolment is 71 among the 18 trials that report a genuine target (sentinel values excluded). 11 of those (61.1%) plan for fewer than 100 participants.
-
Neurofibromatosis Type 1 research is mostly interventional.
13 interventional and 5 observational studies make up this index (72.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Neurofibromatosis Type 1 Tumor Early Detection Study
David Miller
NCT06515860
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
National Cancer Institute (NCI)
NCT06880991
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
National Cancer Institute (NCI)
NCT06507748
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Healx Limited
NCT06541847
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Nicole Baca
NCT04763109
Natural History Study of Cutaneous Neurofibromas in People With NF1
Johns Hopkins University
NCT05581511
Natural History Study of Patients With Neurofibromatosis Type I
National Cancer Institute (NCI)
NCT00924196
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
NCT03871257
Interventions for Reading Disabilities in NF1
Vanderbilt University
NCT02964884
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Cancer Institute (NCI)
NCT01362803
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
AstraZeneca
NCT05309668
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
NCT05101148
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03190915
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
Kristina Hardy
NCT02944032
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
NCT02777775
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Cancer Institute (NCI)
NCT02471339
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
NCT00304083
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
NCT02700230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurofibromatosis Type 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurofibromatosis Type 1 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurofibromatosis Type 1 page
18 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Neurofibromatosis Type 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neurofibromatosis Type 1 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurofibromatosis Type 1 condition card totals 18 registered trials; most-linked intervention Quality-of-Life Assessment; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.